Analysis of the efficacy, effects and common side effects of Bestifan

As an inhibitor of HIF-2α, Belzutifan has shown unique efficacy in the treatment of malignant and benign tumors related to VHL syndrome. The high precision of its targeting mechanism provides new ideas for the treatment of solid tumors such as renal cell carcinoma (RCC). In recent years, the drug has been approved by the FDA for locally progressive renal cancer, retinal or central nervous system hemangioblastoma caused by VHL disease, marking the entry of hypoxia pathway targeted therapy into the clinical stage.

In terms of efficacy, Bestivan inhibits the expression of genes related to adaptability to hypoxic environments by blocking the binding of HIF-2α to its transcription partner HIF-1β, including promoting angiogenesis, erythropoiesis, tumor cell proliferation and other signals. This mechanism of action enables it to play a direct inhibitory effect on the continuous tumor activation caused by the inactivation of VHL protein. Compared with traditional targeted drugs, bezutivan has higher selectivity and fewer "bypass activation" problems for tumor cells carrying VHL gene mutations, reducing the chance of drug resistance.

Clinical data shows that bezotivan can achieve tumor shrinkage, lesion stabilization or even complete remission in multiple lesions, and shows a high degree of disease control ability in non-metastatic early-stage renal cancer. It is especially suitable for patients who are not suitable for surgery or have multiple lesions. At the same time, the oral drug form facilitates long-term treatment and avoids the trauma caused by repeated interventional treatments or surgeries.

But like most targeted drugs, bestivan also has its own specific side effect profile. Common adverse reactions include mild to moderate anemia. This is because the HIF pathway plays a key role in regulating erythropoietin expression, and drug intervention may lead to reduced red blood cell production. In addition, fatigue, headache, shortness of breath, hypernatremia, etc. can also be seen in some patients and can usually be alleviated through supportive treatment or dose adjustment.

Reference materials:https://www.welireg.com/